|This Slide: #4 of 100|
Slide #4. Akorn, Inc. — VersaPharm
Akorn, Inc. (NASDAQ:AKRX)
Akorn, Inc. (NASDAQ:AKRX) today announced that it has entered into a definitive agreement to acquire VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440 million in cash.
Akorn is a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Co.'s segments include: Prescription Pharmaceuticals, which primarily consists of generic and branded prescription pharmaceuticals in a variety of dosage forms including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals, nasal sprays and otics; and Consumer Health, which primarily consists of branded and private-label over-the-counter products and animal health products dispensed by veterinary personnel.
AKRX SEC Filing Email Alerts Service
Open the AKRX Page at The Online Investor »
Hold (2.40 out of 4)
(ranked lower than approx. 87% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite